

Special Issue

Personalized Medicine for Otolaryngology (ENT)

Message from the Guest Editor

In the last decade, personalized medicine has shifted the traditional “one size/drug fits all” approach into a more stratified therapeutic strategy, which includes prevention, diagnostics, therapy/treatment, and rehabilitation. Personalized medicine aims to change the healthcare landscape, focusing on the individual patient to empirically identify the most effective health and wellness strategies at a personal level. This approach will also assess if the cost of treatments are validated by their utility, as well as opening doors for innovations regarding diseases where no current treatments change the course of the disease, such as head and neck squamous cell carcinoma, tinnitus, or hearing loss.

This Special Issue aims to provide a broad overview of personalized medicine across all subspecialties of otolaryngology, different clinical or basic science methodology, as well as cutting edge therapeutic options, such as gene/stem cell therapy. Moreover, this Special Issue will cover all aspects of personalized treatment or rehabilitation options in the field of otolaryngology and their positive impact on the patient's survival or quality of life.

Guest Editor

Dr. Mehdi Abouzari

Division of Neurotology and Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, CA 92697, USA

Deadline for manuscript submissions

closed (30 April 2026)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/200380

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).